Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...

Higher dietary magnesium intake is associated with a reduced risk of frailty in patients with chronic obstructive pulmonary ...

For patients with severely compromised lung function, an important treatment is supplemental oxygen. Flawed Medicare payment ...

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...

While smoking remains the leading risk factor for COPD, non-smokers should be aware of other environmental and occupational ...

Introduction Inspiratory muscle training (IMT) has been applied during pulmonary rehabilitation in patients with chronic obstructive pulmonary disease (COPD). However, it remains unclear if the ...

Obesity has this year overtaken smoking as Australia's leading risk factor contributing to disease, according to a national ...

A review of the management of COPD is presented, with particular emphasis on the effect on the approach to management of new information which has become available in the 5 years since the BTS ...